|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||58.69 - 59.27|
|52 Week Range||50.27 - 67.71|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||N/A|
|Expense Ratio (net)||N/A|
In this daily bar chart of BDX, below, we can see that prices made a peak in early October and prices weakened into late December/early January. The daily On-Balance-Volume (OBV) line has declined since early April and suggests that sellers of BDX have been more aggressive. In this weekly bar chart of BDX, below, we can see a potential topping or bearish pattern from late 2017 with a possible "neckline" across the $210 level.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would hold off for now from Village Farms International Inc (NASDAQ: VFF ). He is not a buyer of Sailpoint Technologies Holdings Inc ...
Becton Dickinson and Co’s (NYSE: BDX ) stock has lost more than 10 percent since March 15 in response to the FDA update on drug-coated balloons, or DCBs. The market seems to have overreacted to the news, ...
The Franklin Lakes, New Jersey-based company said it had a loss of 7 cents per share. Earnings, adjusted for one-time gains and costs, came to $2.59 per share. The results topped Wall Street expectations. ...
is expected to report quarterly earnings of $2.58 a share on sales of $4.2 billion before the market opens on Thursday, based on a FactSet survey of 19 analysts. The stock has fallen 4.1% since the company last reported earnings on Feb. 5. Becton, Dickinson is currently trading at a price-to-forward-earnings ratio of 17.9 based on the 12-month estimates of 20 analysts surveyed by FactSet.
FRANKLIN LAKES, N.J. , April 29, 2019 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on June ...
A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.
The Franklin Lakes, New Jersey-based company said it had net income of $2.05 per share. Earnings, adjusted for non-recurring costs and restructuring costs, were $2.70 per share. The medical device manufacturer ...
Medical device companies need to focus on value and disease prevention or their products risk becoming commodities, according to a recent report by consulting firm KPMG. Warning! GuruFocus has detected 3 Warning Signs with ZBH.
A divided U.S. appeals court on Wednesday dealt a setback to older job applicants, saying they cannot invoke a federal law against age bias in employment to challenge hiring policies they believe have a discriminatory impact. In an 8-4 decision, the 7th U.S. Circuit Court of Appeals in Chicago said the "plain language" of the Age Discrimination in Employment Act ("ADEA"), which forbids discrimination against people 40 and older, showed that Congress intended that law to cover current employees, not outside job applicants. It also reinstated a federal district judge's dismissal of Illinois resident Dale Kleber's disparate impact claim against CareFusion Corp, a unit of medical device maker Becton Dickinson and Co.
said it expects fiscal first-quarter results above Wall Street's expectations. The multinational medical technology company expects quarterly revenue of $4.16 billion for the first fiscal quarter ended Dec. 31, an increase of 35.1% from the prior year, primarily due to the acquisition of C. R. Bard, the company said. Preliminary earnings per share of $2.70 increased 8.9% from $2.48 the prior year, or 14.9% on a currency-neutral basis.
According to GuruFocus' list of 52-week lows, these Guru stocks have reached their 52-week lows. The price of Becton, Dickinson and Co. (BDX) shares has declined to close to the 52-week low of $216.99, which is 21.5% off the 52-week high of $265.87. The company has a market cap of $58.47 billion.
Becton, Dickinson and Co is a healthcare company. The dividend yield of Becton, Dickinson and Co stocks is 1.22%. Becton, Dickinson and Co had annual average EBITDA growth of 4.60% over the past ten years.
Next year's revenue may not be so hot, but earnings should grow nicely as the company captures synergies and pays down debt.
Jensen Quality Growth Fund Portfolio Manager Allen Bond talks inflation and interest rates with Yahoo Finance's Adam Shapiro and Julie Hyman and Cumberland Advisors Chairman & Chief Investment Officer David Kotok.